... or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. UFT® Leucovorin Fluoropyrimidines Colorectal cancer 30 6 2009 ONCOLOGY...

... prognostic factor. The present finding of a wide range in these enzyme expressions in RCC suggests that a certain subpopulation with a high TP/DPD ratio has potential responsiveness to fluoropyrimidines, especially 5’-deoxy-5-fluorouridine and capecitabine. Monotherapy with hormones, anticancer drugs...

...Rogelio A. Brito; Diana Medgyesy; Thomas H. Zukowski; Melanie E Royce; Farhad Ravandi-Kashani; Paulo M. Hoff; Richard Pazdur After nearly four decades of clinical experience with the fluoropyrimidines, 5-fluorouracil (5-FU) remains an integral part of chemotherapy for colorectal cancer. A range...

... combination therapies involving other agents that are active in colorectal cancer, including camptothecin and its analogues, oxaliplatin and radiotherapy. Further studies of Xeloda can be expected with other diseases known to be responsive to fluoropyrimidines, together with diseases traditionally thought...

...Jaap Verweij 5-Fluorouracil (5-FU) plays an important role in the treatment of several tumor types, particularly colorectal cancer and breast cancer. Xeloda ® (capecitabine; 5′-deoxy-5-fluoro-N-[(pentyloxy)carbonyl-cytidine]) is a new rationally designed fluoropyrimidine carbamate...